CHO Pharma Inc 6586
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 40
- Website
- http://www.chopharma.com
Comparables
Valuation
|
Metric
|
6586
|
4162
|
NYKD
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 35.13 | — |
Price/Book Value | 4.17 | 3.28 | 0.95 |
Price/Sales | — | 14.86 | 24.14 |
Price/Cash Flow | — | 33.66 | — |
Price/Earnings
6586
4162
NYKD
Financial Strength
|
Metric
|
6586
|
4162
|
NYKD
|
|---|---|---|---|
Quick Ratio | 23.03 | 12.98 | 9.28 |
Current Ratio | 23.43 | 13.07 | 9.28 |
Interest Coverage | −730.54 | 1,511.77 | — |
Quick Ratio
6586
4162
NYKD
Profitability
|
Metric
|
6586
|
4162
|
NYKD
|
|---|---|---|---|
Return on Assets (Normalized) | −10.40% | 8.92% | −17.82% |
Return on Equity (Normalized) | −10.99% | 9.41% | −22.35% |
Return on Invested Capital (Normalized) | −12.17% | 8.03% | −25.52% |
Return on Assets
6586
4162
NYKD
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zxwrpdby | Vvx | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dlqdpsvtn | Tqqlkfl | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Bltjdbzcb | Tlllkt | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Kmbbxfh | Rmclsw | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Zgnbvdgj | Yqcq | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Ylptkms | Vmz | $29.2 Bil | |||
| Moderna Inc
MRNA
| Gwnrgztz | Jrcg | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Dxthlqk | Cbjy | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dbdzrbsfd | Frzbskp | $13.2 Bil | |||
| Incyte Corp
INCY
| Lsvyphtvl | Kqpjjm | $13.0 Bil |
United States